Valuation: Cytosorbents Corporation

Market Cap 12.95M 11.51M 10.67M 9.71M 18.32M 1.23B 18.61M 128M 50.29M 641M 48.61M 47.57M 2.04B P/E 2026 *
-0.93x
P/E 2027 * -4.57x
Enterprise Value 12.95M 11.51M 10.67M 9.71M 18.32M 1.23B 18.61M 128M 50.29M 641M 48.61M 47.57M 2.04B EV / Sales 2026 *
0.33x
EV / Sales 2027 * 0.29x
Free-Float
83.75%
Yield 2026 *
-
Yield 2027 * -
1 day+34.31%
1 week+8.44%
Current month+5.38%
1 month-28.65%
3 months-42.92%
6 months-68.86%
Current year-67.85%
1 week 2.84
Extreme 2.8402
4.6
1 month 2.84
Extreme 2.8402
5.79
Current year 2.84
Extreme 2.8402
16.89
1 year 2.84
Extreme 2.8402
18
3 years 2.84
Extreme 2.8402
43
5 years 2.84
Extreme 2.8402
132.8
10 years 2.84
Extreme 2.8402
299
Manager TitleAgeSince
Chief Executive Officer 55 24/07/2008
Director of Finance/CFO 62 14/08/2024
President 68 28/04/2020
Director TitleAgeSince
Director/Board Member 77 25/07/2011
Director/Board Member 55 01/01/2009
Director/Board Member 65 13/11/2014
Date Insider Type Main position Quantity % Market Cap. Importance
15/9/26 Buy

Chief Executive Officer

3,774 0.0060%
15/9/26 Buy

Director

2,500 0.0040%
14/9/26 Buy

Chairperson

2,073 0.0033%
Change 5-day change 1-year change 3-year change Capi.($)
+34.31%+8.44%-76.79%-87.55% 12.95M
-0.93%+4.86%+28.03%+42.34% 255B
-1.06%+4.20%+9.56%+8.07% 161B
-0.27%+0.65%-4.36%+54.96% 151B
+0.57%+3.88%-55.27%-12.03% 64.33B
+1.47%+5.90%-13.25%-13.43% 51.9B
-0.85%+4.81%+9.39%+49.25% 50.25B
-1.70%+1.63%+16.02%+23.13% 49.92B
-1.47%+1.42%+21.88%+53.89% 48.77B
-1.62%+0.73%+30.59%+70.27% 42.93B
Average +2.84%+4.13%-3.42%+18.89% 87.5B
Weighted average by Cap. -0.69%+4.13%+8.51%+32.21%

Financials

2026 *2027 *
Net sales 38.88M 34.56M 32.03M 29.15M 55M 3.69B 55.88M 385M 151M 1.93B 146M 143M 6.14B 44.16M 39.26M 36.39M 33.1M 62.47M 4.19B 63.47M 437M 171M 2.19B 166M 162M 6.97B
Net income -13.91M -12.36M -11.46M -10.43M -19.68M -1.32B -19.99M -138M -54.01M -689M -52.21M -51.09M -2.2B -2.77M -2.46M -2.28M -2.08M -3.92M -263M -3.98M -27.45M -10.76M -137M -10.4M -10.18M -438M
Net Debt - -
Projected Income Statement - Annual - Cytosorbents Corporation
Logo Cytosorbents Corporation
CytoSorbents Corporation is engaged in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery through blood purification. The Company’s blood purification technologies are based on biocompatible, highly porous polymer beads that can actively remove toxic substances from blood and other bodily fluids by pore capture and surface adsorption. Its lead product, CytoSorb, is an extracorporeal blood purification cartridge to reduce cytokine storms in common critical illnesses that can lead to massive inflammation, organ failure and patient death. Its products also include ECOS-300CY, VetResQ, DrugSorb-ATR, and PuriFi. DrugSorb-ATR is an investigational device that uses equivalent polymer technology to CytoSorb to address a large unmet need for blood thinner reversal in cardiothoracic surgery. ECOS-300CY is used to reduce cytokines and other inflammatory mediators when used in an ex vivo organ perfusion system.
Employees
129
Date Price Change Volume
16/10/26 US$4.110 +34.31% 684,831
15/10/26 US$3.060 -0.97% 10,827
14/10/26 US$3.090 -10.69% 16,511
13/10/26 US$3.460 -3.62% 10,170
12/10/26 US$3.590 -5.28% 8,340
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
MarketScreener Ratings - Cytosorbents Corporation
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
1
Last Close Price
4.110USD
Average target price
47.50USD
Spread / Average Target
+1,055.72%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Cytosorbents Corporation
  1. Stock Market
  2. Stocks
  3. CTSO Stock